Prostate MRI for local staging and surgical planning in prostate cancer

Similar documents
Prostate MRI: Who needs it?

Anatomic Imaging of Prostate Cancer

Case Discussions: Prostate Cancer

1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct margin.

Clinical Case Conference

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer

Stephen McManus, MD David Levi, MD

Utility of Prostate MRI. John R. Leyendecker, MD

MR-US Fusion Guided Biopsy: Is it fulfilling expectations?

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

Prostate Cancer: 2010 Guidelines Update

Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144

My biopsy shows prostate cancer: How bad is it? How to stage prostate cancer

Essential Initial Activities and Clinical Outcomes

Problems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.

PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging

Detection & Risk Stratification for Early Stage Prostate Cancer

Personalized Therapy for Prostate Cancer due to Genetic Testings

PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW

Active Surveillance for Intermediate Risk Prostate Cancer

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)

Prostate Cancer DFP Case of the Week

Detection, Screening and. Jelle Barentsz, Radboudumc, Nijmegen, NL

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

State-of-the-art: vision on the future. Urology

Prostate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers

Prostate MRI: Screening, Biopsy, Staging, and Ablation

Diffusion Weighted Imaging in Prostate Cancer

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Optimizing Implementation of Prostate MRI. Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Controversies in Prostate Cancer Screening

Supplemental Information

MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know

PSMA PET in patients with prostate cancer

How do I control (monitor) patients receiving TRT after prostate cancer treatment

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease

Conceptual basis for active surveillance

Prostate Cancer Incidence

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Debate: Whole pelvic RT for high risk prostate cancer??

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Screening and Diagnosis Prostate Cancer

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

Sorveglianza Attiva update

Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Multiparametric Prostate MRI: PI-RADS V.2

Trends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance

Chapter 2. Understanding My Diagnosis

A biopsy can be avoided in patients with positive DRE and negative MRI. Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia

ACTIVE SURVEILLANCE FOR PROSTATE CANCER

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template

Percentage of Positive Biopsy Cores Predicts Presence of a Dominant Lesion on MRI in Patients with Intermediate Risk Prostate Cancer

Providing Treatment Information for Prostate Cancer Patients

The current status of MRI in prostate cancer

#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats

SEER Summary Stage Still Here!

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:

Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality

Current Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

MRI and Fusion biopsies. K Sahadevan Consultant Urologist

D. J. Margolis 1, S. Natarajan 2, D. Kumar 3, M. Macairan 4, R. Narayanan 3, and L. Marks 4

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Hugh J. Lavery, M.D., Fatima Nabizada-Pace, M.P.H., John R. Carlucci, M.D., Jonathan S. Brajtbord, B.A., David B. Samadi, M.D.*

Correspondence should be addressed to Taha Numan Yıkılmaz;

Multi-parametric magnetic resonance imaging as a management decision tool

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Inception Cohort. Center for Evidence-Based Medicine, Oxford VIP-- Inception Cohort (2008) Nov Dec

GUIDELINES ON PROSTATE CANCER

Multiparametric MRI diagnostic value in a case of prostate cancer

Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Fellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018

PCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."

Prostate Biopsy in 2017

Clinical Prostate Cancer Imaging

PROSTATE CANCER SURVEILLANCE

MEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING PROSTATE/MULTIPARAMETRIC MRI EFFECTIVE DATE: 06/21/18

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer

How to detect and investigate Prostate Cancer before TRT

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

Prostate Cancer Local or distant recurrence?

Dong Hoon Lee, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong and Byung Ha Chung

Adam Raben M.D. Helen F Graham Cancer Center

Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2

GUIDELINEs ON PROSTATE CANCER

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

Prostate Cancer. David Wilkinson MD Gulfshore Urology

Transcription:

Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor

Disclosures None

Objectives Epidemiologic trends in prostate cancer Role of stage in risk and treatment Accuracy of multiparametric MRI in defining stage Use of MRI in surgical planning

Prostate Cancer Epidemiology Mortality decreasing 3.5%/y since 1995 [SEER]

Prostate Cancer Stage Migration Hu JC, JAMA Onc, 2017

Prostate Cancer Stage and Risk D Amico Risk Low PSA <10, Gleason 6, T2a Intermediate PSA 10-20, Gleason 7, T2b High PSA 20, Gleason 8, T2c

Prostate Cancer Stage and Risk CAPRA Score Nomograms (e.g., MSKCC) NCCN Classification, 2016 Scoring system based on age, PSA, primary pattern 4 or 5, clinical stage, % involvement of biopsy core Low: Score 0-2 Intermediate: Score 3-5 High: Score 6-10 Calculates probability of adverse pathology, disease progression, and/or cancer specific survival based on age, PSA, clinical stage, Gleason score, %core positive Very Low Risk: T1c, Gleason 6, PSA <10, <3 cores with 50% cancer in each, and PSA density <0.15 ng/ml/prostate volume Low Risk: T1-T2a, Gleason 6, and PSA <10 Intermediate Risk: T2b-T2c, Gleason 7, or PSA 10 20 High Risk: T3a, Gleason 8 10, or PSA >20 Very High Risk: T3b-T4, primary Gleason pattern 5, or >4 cores with Gleason 8-10

Potential Decision Point? Guideline Panel AUA/ASTRO EUA NCCN Recommendation Adjuvant XRT should be discussed/offered for men with positive margin, extraprostatic extension, or seminal vesicle invasion after radical prostatectomy For men with pt3, particularly with positive margins, can be offered: Adjuvant radiation therapy Careful biochemical monitoring with early salvage before PSA exceeds 0.5 ng/ml For men with pt3 or positive margins: Radiation therapy Observation Also implications on duration of ADT with XRT

Local Staging with DRE/US

Multiparametric Prostate MRI AUA Standard Operating Procedures, 2017 3.0T vs. 1.5T +/- Endorectal Coil T1/T2 weighted imaging plus Diffusion weighted and Dynamic contrast enhanced MRI sequences PI-RADS version 2

MRI Grading: PI-RADS v2 T2-weighted imaging Low signal intensity = dark High signal intensity = bright Diffusion-weighted imaging Apparent diffusion coefficient (ADC) map High b-value images (i.e., > 1400 sec/mm 2 ) Dynamic contrast enhancement Early enhancement in a lesion not consistent w/ BPH on T2WI

MRI Grading: PI-RADS v2

MRI Biopsy Trends

MRI Indicated for Most Men High Risk Intermediate Risk Grade 2 Grade 3 Low Risk Previous Negative

CAN WE USE MULTIPARAMETRIC MRI FOR LOCAL STAGING & SURGICAL PLANNING?

MRI for Local Staging Gupta et al, 2014: 60 men with MRI and RP 28.6% of men with <50% T1-T2 had OC while 67.9% of men with >50% T1-T2 had OC 83.3% agreement between MRI and RP T2 vs. T3 AUC 0.62 for Partin table vs. 0.82 for MRI MRI Staging T1 T2a-b T2c T3a T3b T4 No suspicious lesions Unilateral lesion highly suspicious Bilateral lesions highly suspicious High degree of suspicion for ECE High degree of suspicion for SVI Invades adjacent structures

MRI for Local Staging Study MRI Outcome Sens Spec PPV NPV Notes Gupta, 2014 3T (no coil) T2 81.6 86.4 91.2 73.1 MRI staging Gupta, 2014 3T (no coil) EPE 77.8 83.4 66.7 89.7 system by 1 MD Raskolnikov, 2015 Boesen, 2015 3T with coil EPE 48.7 73.9 35.9 82.8 2 MD; May be improved with target bx results 3T (no coil) EPE 74 88 77 86 2 MD/different experience Feng, 2015 3T (no coil) EPE 70.7 90.6 57.1 95.1 1 MD; better for non-focal and non-apex Soylu, 1.5T with coil SVI 78 96.3 82 95.4 2 MD/different experience; DWI improves

MRI/Pathology Correlates

MRI/Pathology Correlates Extraprostatic Extension, Non-nerve sparing

MRI/Pathology Correlates

MRI/Pathology Correlates Partial nerve-sparing, Organ-Confined Disease

Predicting T3 with Nomogram

Proportion with T3, % Predicting T3 disease with MRI

MRI for Surgical Planning UCLA study of 105 men 105 men treated with RALP MR with 1.5T and endorectal coil 50% sensitivity, 97% specificity for T3 Surgical plan changed 27% of time 61% changed to nerve-sparing, 39% to nonnerve-sparing No positive margins on changed cases McClure, Radiology, 2012

Take Home Points Diagnosing T2 vs T3 may be increasingly vital given epidemiology and treatments Multiparametric MRI appears to offer moderate accuracy and may outperform existing clinical tools Impact on clinical outcomes warrants further study

Special Thanks Sara Wobker, MD Chris Koller, MS4 Eric Wallen, MD

QUESTIONS/COMMENTS?